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Based  on  current  studies  on  the  effects  of  single  dose  vaccines  on  antibody  production,  Latin  American
countries  have adopted  a single  dose  vaccine  program.  However,  no  data  are  available  on  the  activation
of  cellular  response  to a  single  dose  of  hepatitis  A. Our  study  investigated  the  functional  reactivity  of  the
memory  cell  phenotype  after  hepatitis  A virus  (HAV)  stimulation  through  administration  of the  ﬁrst  or
second dose  of HAV  vaccine  and  compared  the  response  to  that  of  a baseline  group  to an initial  natural
infection.  Proliferation  assays  showed  that  the  ﬁrst vaccine  dose  induced  HAV-speciﬁc  cellular  response;
this response  was  similar  to that  induced  by  a second  dose  or  an  initial  natural  infection.  Thus,  from
the  ﬁrst  dose  to the  second  dose,  increase  in  the  frequencies  of  classical  memory  B cells,  TCD8  cells,  and
central memory  TCD4  and  TCD8  cells  were  observed.  Regarding  cytokine  production,  increased  IL-6,  IL-ffector memory cells
ellular response
10, TNF,  and  IFN  levels  were  observed  after  vaccination.  Our  ﬁndings  suggest  that a  single  dose  of HAV
vaccine  promotes  HAV-speciﬁc  memory  cell  response  similar  to that  induced  by  a  natural  infection.  The
HAV-speciﬁc  T cell  immunity  induced  by primary  vaccination  persisted  independently  of  the  protective
plasma  antibody  level.  In  addition,  our  results  suggest  that  a single  dose  immunization  system  could
serve  as  an  alternative  strategy  for  the  prevention  of hepatitis  A  in  developing  countries.
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. Introduction
Vaccines against hepatitis A (HAV) were ﬁrst developed in
he 1980s and were licensed for use in the early 1990s [1].
here is only one serotype of HAV, although multiple strains of
AV are found worldwide. Therefore, a vaccine prepared from
 strain with a different geographic origin or from a different
irus isolate can still protect against infection by hepatitis A
2,3].
Immunization programs for children (≥1 year of age) have
een introduced in several countries [4–6]. A two-dose vaccina-
ion schedule is generally used at an interval of 6–18 months
etween the ﬁrst (primary) and second (booster) doses. The
ffectiveness of the HAV vaccine is attributed to the reduc-
ion in the reported worldwide incidence of acute hepatitis A
4,7–9].
Several middle-income regions throughout the world, includ-
ng Asia, Latin America, Eastern Europe, and the Middle East, have
ndergone a transition in the epidemiology of HAV, in which
he number of young subjects susceptible to HAV infection has
ubstantially increased. During a meeting of the World Health
rganization (WHO) Strategic Advisory Group of Experts (SAGE)
n Immunization [10], it was noted that populations in these
ountries may  beneﬁt the most from large-scale HAV vaccination
rograms. However, one of the main barriers to the introduction
f universal hepatitis A immunization of children in developing
ountries is high vaccine prices. A single dose schedule would
emove barriers to the use of these vaccines for public health pur-
oses by reducing the cost associated with immunization. The
fﬁcacy and safety of both one- and two-dose inactivated HAV
accines have already been established [11–15]. At present, two
atin American countries have adopted single dose hepatitis A
hildhood immunization programs. Argentina was  a pioneer in
mplementing this vaccination schedule in 2005. After two  years,
ith a vaccination coverage of 95%, the incidence of symptomatic
iral hepatitis A decreased by >80% in all age groups [16]. Brazil
egan HAV vaccination in 2014. This decision was based on cost-
eneﬁt studies showing that national universal HAV vaccination
ould have an important impact on the epidemiology of this
isease [17].
The duration of immune protection after HAV vaccination
as been investigated. Two of the longest follow-up studies in
dults reported the persistence of anti-HAV antibodies up to at
east 17 years after receiving a monovalent inactivated HAV vac-
ine (HavrixTM, GlaxoSmithKline Vaccines, Belgium) according to
 two-dose schedule. Hens and colleagues [44] projected dura-
ion of protection of at least 25 years in ≥95% of the vaccines
10,14,15]. However, only humoral responses have been consid-
red when verifying protection; cellular responses have not been
ssessed. This knowledge would be relevant for the investigation
f low responsiveness or non-responsiveness to the HAV vaccine,
s this phenomenon is often observed in response to different
accines, affecting 1–10% of all vaccines [18–20]. Garner-Spitzer
nd colleagues [26] demonstrated a good correlation between the
ntibody concentration and the cellular response; speciﬁcally, low
ntibody production was associated with a low antigen-speciﬁc
esponse after a booster vaccination. However, no studies have
nvestigated activation of the memory T cell response proﬁle after
 single HAV vaccine dose. Here, we investigated antigen-speciﬁc
emory cell proliferation in seronegative individuals prior to and
ollowing immunization with a formalin-inactivated HAV vaccine.
or the ﬁrst time, a single HAV vaccine dose was shown to effec-
ively induce a memory T cell response after stimulation with a
ild HAV strain. The T cell response after a single HAV vaccine dose
as similar to that observed after both the booster dose and HAV
nfection.3 (2015) 3813–3820
2. Materials and methods
2.1. HAV vaccination
Twenty-two healthy individuals (21.0 ± 0.45 years) who were
seronegative for anti-HAV were randomly selected and immunized
with an inactivated hepatitis A vaccine (Merck Sharp & Dohme,
West Point, PA, USA, lot 0526F) using a 0–6 month schedule, as pre-
viously described [5]. Of these individuals, 12 (54.5%) were female.
The vaccine contained 50 U/1.0 mL  of inactivated hepatitis A anti-
gen adsorbed to 0.45 mg  of aluminum hydroxide (adult dose) and
was administered intramuscularly into the deltoid region of the
left arm. The mean body mass index (BMI) of the participants was
21.95 ± 0.5, and none of the participants had a history of drug use.
To investigate the post-vaccination immune response, vaccinated
individuals were monitored three times throughout the study: time
0 (T0), before administering the 1st dose of the vaccine; time 1 (T1),
6 months after administering the 1st dose and before administering
the 2nd dose; and time 2 (T2), 24 months after administering the
2nd dose. All vaccinated individuals were monitored for 30 months.
2.2. Acute hepatitis A patients
Twenty outpatients (25.62 ± 2.65 years) with self-limited acute
hepatitis A attending the viral hepatitis ambulatory clinic of the
Oswaldo Cruz Institute (FIOCRUZ) were recruited as the control
group. Of these individuals, 9 (45%) were female. Acute hepatitis
A cases were deﬁned as follows: (1) by the use of a commercially
available enzyme-linked immunosorbent assay (ELISA) kit for anti-
HAV IgM (Abbott, USA); (2) by the observation of clinical features
of acute-onset hepatitis within 2–8 weeks in a previously healthy
individual; and (3) by the observation of aminotransferase levels
that were at least 10-fold higher than the upper limit of normal
[21–24]. Patients exhibiting co-infection with other forms of viral
hepatitis were not included.
2.3. Blood sample collection and processing
Blood samples (∼40 mL)  were collected from the vaccinated
individuals via venipuncture (VacutainerTM, Becton Dickinson,
Franklin Lakes, NJ, USA) at three time points (T0, T1, and T2) and
at the onset of acute hepatitis during the clinical examination of
the control group. Signed informed consent was obtained from
all participants. The study protocol was  approved by the National
Commission on Ethics in Research (CONEP) and by the institu-
tional review boards of FIOCRUZ (protocol #222-03 and 401-07).
The blood samples were centrifuged (224 g), and the plasma was
separated and frozen at −20 ◦C. Peripheral blood mononuclear cells
(PBMCs) were separated via centrifugation in Ficoll density gra-
dient medium (30 min  at 400 g at 18 ◦C). Freezing medium (10%
dimethylsulfoxide (DMSO), and 90% fetal bovine serum (FBS)) was
added, and the cells were stored in liquid nitrogen until the assay
was conducted. The plasma and PBMC samples used for the differ-
ent assays were thawed only once.
2.4. Laboratory tests
2.4.1. Anti-HAV detection
Plasma samples were assayed for total anti-HAV levels
using a commercial competitive ELISA kit (Bioelisa HAV-
EIA, Biokit, Barcelona, Spain), and a commercial immunoassay
(ImmunoComb®II HAV Ab, Orgenics, Israel) was used to retest the
samples displaying negative results. The detection limits of the lots
used in the Bioelisa HAV-EIA were 75 mIU/mL (lot L-0407), and
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7 mIU/mL (lot I-3308), and the ImmunoComb®II HAV Ab assay
as used at a limit of detection of 10 IU anti-HAV antibodies/L [25].
.4.2. Antigen-speciﬁc proliferation assay
PBMCs were suspended in RPMI 1640 medium (Sigma-Aldrich,
SA) at a concentration of 5 × 106 cells/mL and mixed with an equal
olume of a 10 mM working solution of carboxyﬂuorescein succin-
midyl ester (CFSE-FITC; Molecular Probes, Invitrogen, USA), which
as diluted to 1/1000 for all analyses. The procedure was per-
ormed according to the manufacturer′s instructions. PBMCs were
uspended in RPMI 1640 medium supplemented with 110 U/mL
enicillin, 100 g/mL streptomycin, and 10% heat-inactivated FBS
t a concentration of 2.5 × 106 cells/mL. Non-CFSE-labeled cells
ere used as a negative control. The HAF-203 HAV strain was
ropagated in FRhK-4 cells [22]. The virus suspension was  ﬁltered
hrough a 0.22 m ﬁlter (Merck Millipore, USA) and used for poly-
lonal HAV antigen-speciﬁc proliferation (viral titer of 106 HAV
NA copies/mL). The mitogen inducers phytohemagglutinin (PHA)
L1668, Sigma-Aldrich, USA), and lipopolysaccharide (LPS) (L2762,
igma-Aldrich, USA) were used at ﬁnal concentrations of 10 g/mL,
nd 1 ng/mL, respectively, to control clonal proliferation. Prolifer-
ting cell cultures were set up in duplicate at 5 × 105 cells/well in
6-well ﬂat-bottom culture plates. The plates were incubated in a
7 ◦C incubator containing 5% CO2 for 24 h after LPS stimulation,
or 72 h after PHA stimulation or for 96 h after HAV stimulation.
fter incubation, the cells were harvested for use in ﬂow cytometry
ssays.
.4.3. Flow cytometric analysis
A minimum of 20,000 live cells were collected from each sam-
le and assessed using a CyAn ﬂow cytometer (DakoCytomation,
SA). The data were analyzed off-line using Summit version 6.0
oftware (DakoCytomation, USA). PBMCs were labeled with CD4-
ITC (clone MT310), CD8-PerCP (clone DK25), CD22-FITC (clone
KB128), CD45RO-PE (clone UCHL1) (all from DakoCytomation,
SA), CD62L-PE (clone MHCD62L04), CCR7-APC (CD197) (clone
D12), and isotypes (all from eBioscience, San Diego, CA, USA) and
ere then quantiﬁed. The memory cell phenotypes were deﬁned
s previously described [26,27].
Total mononuclear cells were electronically gated using forward
catter (FSC) and side scatter (SSC) properties; cellular debris and
ranular cells were excluded. Based on their FSC and SSC proper-
ies, proliferating cells were deﬁned as described by others [28–30].
he proliferation index (PI), a measure of the frequency of cells that
ave gone through more than three divisions (positive prolifer-
tion, CFSElow), was assessed using a software program (Summit
ersion 6.0) [28–30]. The ﬁnal PI was calculated as the ratio of
he average PI for antigen-stimulated cells to the average PI for
nstimulated cells. The highly expressed surface markers on the
emory T and B cell subsets activated by antigenic stimulation
ere considered for off-line software analysis (Figs. 1 and 2).
.4.4. Cytokine quantiﬁcation assay
Cytokine production was measured using culture supernatant
amples from the proliferation assay. IL-2, IL-4, IL-6, IL-10, IL-
7A, interferon–gamma (IFN), and tumor necrosis factor (TNF)
ere analyzed using a BDTM Cytometric Bead Array (CBA) kit (cat.
560484; BD Biosciences, San Jose, CA, USA).
.5. Statistical analysis
The data are expressed as the mean values ± standard error.
ne-way analysis of variance (ANOVA) was performed for inter-
roup comparisons of vaccinated individuals. If a signiﬁcant
ifference was found, a pair of variables was assessed using the
ilcoxon matched pairs t-test. Differences over time throughout3 (2015) 3813–3820 3815
the vaccination schedule and between the vaccinated subjects and
the acute hepatitis cases were evaluated using the Kruskal–Wallis
test. If a signiﬁcant difference was  found, each pair of variables
was assessed using the Mann–Whitney U-test. The R Project for
Statistical Computing (http://www.r-project.org/) was  used to per-
form statistical analysis. The level of signiﬁcance for all statistical
analyses was deﬁned as a P value <0.05.
3. Results
3.1. Humoral immunity
Total anti-HAV antibodies were detected in 16/22 (72.73%) vac-
cinated subjects after the ﬁrst dose (T1) and in 22/22 (100%)
vaccinated subjects after the second dose (T2). The subjects who
did not display total anti-HAV antibody levels above the limit of
detection after receiving the ﬁrst dose (6/22) were considered as
poor responders.
3.2. HAV-induced clonal proliferation in vaccinated subjects
HAV-speciﬁc cellular response was observed at T1. At this time
point, the PI was  increased by 3.21-fold compared to the PI before
vaccination (T0). No signiﬁcant differences were found in the PI
between T2 and T1 (Table 1). A clonal proliferation response to
mitogens (PHA and LPS) was  apparent at all time points during the
follow-up period (PHA: T0 = 44.61 ± 12.25, T1 = 62.23 ± 15.64, and
T2 = 22.25 ± 9.43; LPS: T0 = 39.57 ± 11.89, T1 = 53.27 ± 13.67, and
T2 = 31.55 ± 10.56).
3.3. Activation of memory cell phenotypes after HAV  stimulation
Table 1 shows the frequencies of T and B cell subsets of memory
cell phenotypes after vaccination with HAV stimulation. Changes in
the frequencies of classical memory TCD4 (CD4+CD45RO+), TCD8
(CD8+CD45RO+), and B cells (CD22+CD45RO+) after vaccination
were observed (Fig. 1). The frequency of HAV-speciﬁc TCD4 cells
was signiﬁcantly increased at T2 (Table 1). HAV-speciﬁc classical
effector memory TCD8 cells and effector memory B cells were acti-
vated at T1 (Table 1).
HAV-speciﬁc central memory T cells exhibiting the phen-
otypes CD4+CD62L+CCR7+ and CD8+CD62L+CCR7+ were also
activated after the ﬁrst dose (Fig. 2). The frequencies of effector
TCD4 (CD62L−CCR7−) and TCD8 (CD62L−CCR7−) cells remained
unchanged after vaccination (Table 1).
3.4. HAV-speciﬁc cytokine production
A signiﬁcant increase in IFN, IL-6, and TNF levels was observed
after the ﬁrst dose. The IL-10 levels were signiﬁcantly increased
after the second dose (Table 1). No change in IL-2, IL-4, or IL-17A
levels was detected at any time during follow-up.
3.5. HAV stimulation in poor responders after the ﬁrst dose
The analysis of HAV-speciﬁc stimulation in the group of
poor responders showed HAV-speciﬁc proliferation (p = 0.0245)
and HAV-speciﬁc central memory TCD4 (p = 0.0164) and TCD8
(p = 0.0170) cell subset activation after the ﬁrst dose compared
with at T0. In this group of individuals, evidence of increase in the
frequencies of classical memory CD4+CD45RO+ cells (p = 0.0386)
and classical memory TCD8 cells (CD45RO+) (p = 0.023) was found.
IL-6 (p = 0.0009), and IFN (p = 0.0006) were the only cytokines
detected. No difference in the clonal proliferation of memory B cells
(CD22+CD45RO+) was  found between T1 and T0 (p = 0.6492).
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Upon comparing the group of poor responders with the group
of individuals who seroconverted after the ﬁrst dose, the only
observed difference was the extent of classical effector memory
B cell activation (Table 2).
3.6. The cellular immune response in acute hepatitis A patients is
similar to that in vaccinated subjects after HAV stimulation
The memory cell phenotypes observed in patients with acute
hepatitis A were the same as those observed in the vaccines after the
ﬁrst vaccine dose, except for the central memory T cell phenotype
(CD62L+CCR7+) (Table 1). Additionally, no signiﬁcant difference
in the production of the anti-viral cytokines IFN and IL-10 was
observed between these two groups. However, the percentages of
effector TCD4 (CD62L−CCR7−) and TCD8 (CD62L−CCR7−) cells were
elevated only in the acute HAV patients. The memory B cell pheno-
type and the cytokine levels (IL-6, IL-10, TNF, and IFN) observed
in the vaccines after receiving the second vaccine dose signiﬁcantly
differed from those detected in the patients with natural HAV infec-
tion (Table 1).
4. Discussion
In this study, we  showed that the extent of functional clonal pro-
liferation after the administration of a single dose of HAV vaccine
was sufﬁcient to sensitize the host immune system and to induce
HAV-speciﬁc immune response. Progressive clonal PBMC prolifera-
tion 2–4 weeks after the ﬁrst dose and 1–4 weeks after the booster
dose has previously been demonstrated [18,19,26]. However, we
demonstrated for the ﬁrst time that the memory T cell proﬁle is
activated following administration of the ﬁrst HAV vaccine dose.
Increases in the frequencies of classical effector memory B and T
cells (CD45RO+) and in the proportions of the TCD4 and TCD8 sub-
sets of HAV-speciﬁc cells expressing the homing receptors CD62L
and CCR7 (central memory T cells) were detected six months after
administering the ﬁrst dose (T1). Notably, the central memory T cell
phenotype (CD62L+CCR7+) remained activated after administering
the booster dose (T2). Limited data are available on the activation
of central memory cells after HAV vaccination. Garner–Spitzer and
colleagues [26] administered a booster dose to individuals who
were previously immunized with an inactivated HAV vaccine. They
observed an increase in the frequency of HAV-speciﬁc TCD4 cells
expressing CD62L but not in the frequency of classical memory B
or T cells in adults below 60 years of age.
Effector cells (CD62L−CCR7−) have been proposed as precursors
of memory cells (CD45RO+) [27]. Thus, when naïve T cells are acti-
vated, they mature into classical memory T cells and differentiate
into central memory T cells and subsequently into T effector cells
[31,32]. In agreement with this understanding, the results obtained
from our in vitro assays suggest that once central memory cells are
activated by HAV using only one dose of HAV vaccine, these cells
activate effector cells in vivo and prevent infection upon subsequent
HAV exposure [33–35].
The cellular response observed in vaccinated subjects at T1
was similar to the HAV-speciﬁc memory lymphocyte activation
(CD45RO+) observed in patients with acute HAV infection (con-
trol group). Previous studies revealed that classical memory T cells
subjected to antigen-speciﬁc activation proliferate approximately 2
weeks after viral infection and remained at a constant level there-
after to confer T cell-mediated immunological protection for the
rest of the subject’s life [27,31,36]. As expected, the numbers of
effector TCD4 and TCD8 cells (CD62L−CCR7−) were not altered after
HAV vaccination but were signiﬁcantly elevated in the acute HAV
patients. Studies explain that these effector T cells are increased
after pathogen exposure as a primary response to contribute to
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Fig. 1. Representative dot plots of HAV-speciﬁc classical memory B, TCD4 and TCD8 cells. Fluorescence-activated cell sorting (FACS) plots showing high CD22/CD45RO
expression in PBMC-gated cells (memory B cells) after HAF-203 stimulation before vaccination (a), 6 months after the 1st dose (b), or 24 months after the 2nd dose (c). FACS
plots  showing high CD4/CD45RO expression in PBMC-gated cells (memory TCD4 cells) after HAF-203 stimulation before vaccination (d), 6 months after the 1st dose (e), or
24  months after the 2nd dose (f). FACS plots showing high CD8/CD45RO expression in PBMC-gated cells (memory TCD8 cells) after HAF-203 stimulation before vaccination
(g),  6 months after the 1st dose (h), or 24 months after the 2nd dose (i).
Table 2
Comparison between poor responders and good responders after HAV stimulation following vaccination with the 1st dose.
Immunological parameter 6 months after the 1st dose (T1) t-test
Poor responders Good responders Good vs Poorp value (95% CI)
Anti-HAV IgG (IU anti-HAV antibodies/L) ≤10 >10a 0.0189 (35.33–55.55)
Proliferation index 2.24 ± 0.33 2.92 ± 0.32 Ns
CD4+CD45RO+ (%) 19.44 ± 7.25 17.33 ± 6.04 Ns
CD8+CD45RO+ (%) 10.33 ± 3.61 8.44 ± 2.44 Ns
CD22+CD45RO+ (%) 2.22 ± 0.42 10.33 ± 2.09 0.0306 (1.46–15.07)
CD4+CD62L+CCR7+ (%) 30.84 ± 1.9 31.49 ± 8.37 Ns
CD8+CD62L+CCR7+ (%) 20.83 ± 1.17 27.31 ± 7.38 Ns
IL-6  (pg/mL) 9,864.0 ± 1,871 10,163 ± 1,062 Ns
IL-10  (pg/mL) 56.58 ± 12.68 55.16 ± 14.04 Ns
IFN  (pg/mL) 265.35 ± 60.8 152.24 ± 72.60 Ns
TNF  (pg/mL) 272.37 ± 165.26 214.90 ± 11.58 Ns
Immunological parameters after HAV stimulation in the poor and good responders during vaccination. The mean values ± standard error obtained in PBMCs stimulated with
HAF-203 before and after administering the 1st dose of inactivated HAV vaccine. The proliferation index, the frequency of memory T cells (CD4+CD45RO+; CD8+CD45RO+;
CD4+CD62L+CCR7+; or CD8+CD62L+CCR7+) and memory B cells (CD22+CD45RO+), and the levels of cytokines were detected in culture supernatants after HAF-203 stimulation
and  were compared using the t-test. T0: non-vaccinated (naïve) samples; T1: samples collected 6 months after the 1st dose of hepatitis A vaccine; all cytokine levels are
expressed in pg/mL; all data on the numbers of cells are presented as frequencies (%) from 20,000 events acquired via ﬂow cytometry. pg/mL = Picograms per milliliter.
Ns  = Not signiﬁcant.
a The “good responders” group was determined using Bioelisa HAV-EIA (Biokit, Barcelona, Spain).
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Fig. 2. Representative dot plots of HAV-speciﬁc central memory TCD4 and TCD8 cells. The dot plot strategy has been applied according to the highest levels of CD4-FITC
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an form the memory pool [27,31,36]. In addition, our results
howed that central memory T cell (CD62L+CCR7+) proliferation
ould not be observed during acute HAV infection, as these cells do
ot exhibit proliferative potential for 6–12 months following virus
xposure [27,31,36].
A signiﬁcant increase in IFN, IL-6, and TNF levels was noted
fter HAV stimulation in PBMC samples obtained at T1, as previ-
usly described by Cederna and colleagues [18] IL-2, IL-10, and IFN
roduction has also been described following the administration of
 booster HAV vaccine dose [26]. HIV-infected children immunized
ith an inactivated HAV vaccine may  display undetectable IL-2, IL-
, IL-5, IL-10, and IFN levels [37]. Similar IL-10 and IFN levels
ere observed at T1 and during the acute phase of HAV infection.
hese results reinforce the contribution of these cytokines to the
rotection provided by the HAV vaccine. Alternatively, a signiﬁcant
ecrease in IL-6 and TNF levels after HAV stimulation was observed
n acute hepatitis patients compared with the vaccines following
he ﬁrst or second vaccine dose. These results can be explained by
he attempts of the immune system to control the inﬂammatory
rocess during HAV infection, as has been described in the litera-
ure [38,39]. The decrease in these cytokines may  also be associated
ith progression of the resolution of acute hepatitis A infection or
ith the sequestration of immune events to the intrahepatic com-
artment, which is the major disease site, as has been described by
thers [38–41].Individuals exhibiting an undetectable humoral response after
AV vaccination have also been reported in other studies
18,19,26]. Antibody levels ranging from 10 to 33 IU/mL using dif-
erent assays have been proposed as the threshold for protectionmetric parameters and using Summit version 6.0 software. (a) FACS plots showing
er the 1st dose (b), or 24 months after the 2nd dose (c). FACS plots showing central
1st dose (e), or 24 months after the 2nd dose (f).
from HAV infection in humans [10]. However, clinical experience
suggests that protection following vaccination may  be present
even in the absence of detectable anti-HAV antibodies using
standard immunoassays [10]. In this study, these subjects, termed
poor responders, were investigated for their cellular immunity.
Although HAV-speciﬁc memory B cells were not signiﬁcantly acti-
vated after the ﬁrst dose, the clonal expansion of HAV-speciﬁc
memory T cells was  observed. In other studies, poor responders
with ongoing T cell activation have been observed after HAV  [18,19]
or hepatitis B vaccination [42].
The indication for a booster dose of inactivated HAV vaccine was
based on early projections of waning antibody levels. However,
long-term follow-up studies showed that 1 dose of HAV vaccine
induces immunological memory and in most cases, the produc-
tion of anti-HAV antibodies that persist for 4–11 years [15,16]. The
results obtained herein extend these ﬁndings and suggest that the
adoption of a single dose immunization system can serve as an
alternative strategy for the prevention of hepatitis A in developing
countries. Moreover, it has been argued that the natural booster
response induced by wild virus circulation in endemic areas could
ensure persistent protection [43].
In summary, the ﬁndings of this study demonstrate that a sin-
gle dose of inactivated HAV vaccine may  induce the proliferation
of HAV-speciﬁc PBMCs, classical memory B and T cells, and cen-
tral memory T cells and the production of cytokines after wild HAV
strain stimulation in susceptible young adults. Additionally, a rel-
evant improvement in terms of the HAV-speciﬁc cellular immune
response was  not observed after administering a booster dose of
inactivated HAV vaccine. These ﬁndings suggest that once acti-
vated, the immune system is able to produce a speciﬁc cellular
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